Insider Selling: InfuSystem Holdings, Inc. (NYSE:INFU) CEO Sells $186,400.00 in Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 20,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $9.32, for a total transaction of $186,400.00. Following the completion of the sale, the chief executive officer now directly owns 436,659 shares of the company’s stock, valued at $4,069,661.88. This represents a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Richard Dilorio also recently made the following trade(s):

• On Wednesday, November 27th, Richard Dilorio sold 5,398 shares of InfuSystem stock. The shares were sold at an average price of $8.87, for a total transaction of $47,880.26.

InfuSystem Price Performance

InfuSystem stock opened at $8.87 on Friday. InfuSystem Holdings, Inc. has a 1 year low of $5.74 and a 1 year high of $10.99. The firm’s 50 day moving average is $7.39. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The company has a market capitalization of $188.47 million, a PE ratio of 147.77 and a beta of 1.45.

Analyst Ratings Changes

INFU has been the topic of several recent analyst reports. B. Riley started coverage on shares of InfuSystem in a research report on Thursday, September 26th. They set a “buy” rating and a $13.00 price objective on the stock. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th.

Institutional Trading of InfuSystem

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its position in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after purchasing an additional 1,626 shares in the last quarter. Williams & Novak LLC bought a new position in InfuSystem during the third quarter valued at approximately $70,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in InfuSystem during the 3rd quarter valued at approximately $87,000. Rhumbline Advisers increased its stake in InfuSystem by 13.8% in the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after acquiring an additional 2,145 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of InfuSystem during the 2nd quarter worth approximately $131,000. 71.13% of the stock is currently owned by institutional investors.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.